AR108370A1 - Compuesto fenólico (5-[(3,4-dihidroxifenil)metiliden]-2,2-dimetil-1,3-dioxano-4,6-diona) y combinación con una benzodiazepina fusionada a 1,4-dihidropiridina - Google Patents

Compuesto fenólico (5-[(3,4-dihidroxifenil)metiliden]-2,2-dimetil-1,3-dioxano-4,6-diona) y combinación con una benzodiazepina fusionada a 1,4-dihidropiridina

Info

Publication number
AR108370A1
AR108370A1 ARP170101153A ARP170101153A AR108370A1 AR 108370 A1 AR108370 A1 AR 108370A1 AR P170101153 A ARP170101153 A AR P170101153A AR P170101153 A ARP170101153 A AR P170101153A AR 108370 A1 AR108370 A1 AR 108370A1
Authority
AR
Argentina
Prior art keywords
phenolic
derivatives
phenolic compound
fusionated
dihidroxifenil
Prior art date
Application number
ARP170101153A
Other languages
English (en)
Spanish (es)
Inventor
Yaquis Alejandro Sal Padrn
Hernndez Ren Delgado
Alfonso Nict Gonzles
Fernndez Pedro Gilberto Brzaga
Rodrguez Abel Mondelo
Navarro Claudia Amanda Canan-Haden
Andreu Gilberto Lzaro Pardo
Fonseca Luis Arturo Fonseca
Guerra Maylin Wong
Snchez Jeney Ramrez
Figueredo Yanier Nuez
Reyes Yamila Verdecia
Rodrguez Estael Ochoa
Original Assignee
Univ La Habana
Centro De Investig Y Desarrollo De Medicamentos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ La Habana, Centro De Investig Y Desarrollo De Medicamentos filed Critical Univ La Habana
Publication of AR108370A1 publication Critical patent/AR108370A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
ARP170101153A 2016-05-04 2017-05-04 Compuesto fenólico (5-[(3,4-dihidroxifenil)metiliden]-2,2-dimetil-1,3-dioxano-4,6-diona) y combinación con una benzodiazepina fusionada a 1,4-dihidropiridina AR108370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2016000059A CU24576B1 (es) 2016-05-04 2016-05-04 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Publications (1)

Publication Number Publication Date
AR108370A1 true AR108370A1 (es) 2018-08-15

Family

ID=60202803

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101153A AR108370A1 (es) 2016-05-04 2017-05-04 Compuesto fenólico (5-[(3,4-dihidroxifenil)metiliden]-2,2-dimetil-1,3-dioxano-4,6-diona) y combinación con una benzodiazepina fusionada a 1,4-dihidropiridina

Country Status (19)

Country Link
US (1) US10722491B2 (enExample)
EP (1) EP3453704B1 (enExample)
JP (1) JP6997995B2 (enExample)
KR (1) KR102416478B1 (enExample)
CN (1) CN109476627B (enExample)
AR (1) AR108370A1 (enExample)
AU (1) AU2017259749C1 (enExample)
BR (1) BR112018072579B1 (enExample)
CA (1) CA3023073C (enExample)
CL (1) CL2018003114A1 (enExample)
CO (1) CO2018011927A2 (enExample)
CU (1) CU24576B1 (enExample)
EA (1) EA037951B1 (enExample)
ES (1) ES2878579T3 (enExample)
MX (1) MX384967B (enExample)
PH (1) PH12018502327A1 (enExample)
SG (1) SG11201809843SA (enExample)
WO (1) WO2017190714A1 (enExample)
ZA (1) ZA201808161B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20160058A7 (es) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
JP2022504852A (ja) * 2018-10-16 2022-01-13 サバン ベンチャーズ プロプライアタリー リミテッド 医療機器の洗浄のための装置および方法
EP4082548A2 (en) * 2019-12-26 2022-11-02 Centro de Investigación y Desarrollo de Medicamentos CIDEM Use of a benzodiazepine derivative and method of treatment of traumatic brain injury
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281714A (en) 1990-08-16 1994-01-25 American Home Products Corporation N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase
MX9204939A (es) 1991-09-06 1993-03-01 American Home Prod Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
ATE122671T1 (de) 1992-07-17 1995-06-15 Biogal Gyogyszergyar Verfahren zur herstellung von 1,3-dioxan-4,6- dionderivaten.
JPH11180975A (ja) 1997-10-13 1999-07-06 Chemiprokasei Kaisha Ltd アミノメチレンジオキサン誘導体、その製造方法および用途
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Also Published As

Publication number Publication date
CU24576B1 (es) 2022-02-04
JP2019516791A (ja) 2019-06-20
KR20210025138A (ko) 2021-03-09
AU2017259749A1 (en) 2018-12-20
EA037951B1 (ru) 2021-06-11
CL2018003114A1 (es) 2019-06-14
CA3023073C (en) 2022-08-30
EA201892462A1 (ru) 2019-07-31
EP3453704A1 (en) 2019-03-13
CO2018011927A2 (es) 2019-02-08
US10722491B2 (en) 2020-07-28
ES2878579T3 (es) 2021-11-19
BR112018072579B1 (pt) 2024-02-20
CU20160059A7 (es) 2017-12-08
AU2017259749B2 (en) 2021-08-19
MX384967B (es) 2025-03-14
WO2017190714A1 (es) 2017-11-09
MX2018013422A (es) 2019-08-16
CN109476627B (zh) 2021-06-15
JP6997995B2 (ja) 2022-02-04
BR112018072579A2 (pt) 2019-02-19
CN109476627A (zh) 2019-03-15
PH12018502327A1 (en) 2019-09-02
CA3023073A1 (en) 2017-11-09
EP3453704B1 (en) 2021-06-16
ZA201808161B (en) 2021-10-27
AU2017259749C1 (en) 2021-12-02
US20190133996A1 (en) 2019-05-09
SG11201809843SA (en) 2018-12-28
KR102416478B1 (ko) 2022-07-04

Similar Documents

Publication Publication Date Title
PE20181205A1 (es) Nuevos compuestos de espiro[3h-indol-3,2'-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
PY1909256A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
CL2017002153A1 (es) Compuestos bicíclicos de sulfonamida cetona
MX2017002260A (es) Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
PY1638186A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
DOP2014000230A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
AR125457A2 (es) Compuestos inhibidores dobles de magl y faah y composición farmacéutica
CR20130415A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR090955A1 (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20190042A7 (es) Compuestos derivados de naftiridinona
CL2018003114A1 (es) Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular.
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CO2021017154A2 (es) Profármacos de moduladores del receptor de nmda campo de la invención
CU20160142A7 (es) Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4 dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
CU20160058A7 (es) Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular

Legal Events

Date Code Title Description
FB Suspension of granting procedure